Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shouyao Holding

Request full access

Shouyao Holding is a tumor and diabetes drug research and development company

Dongcheng District, ChinaFounded 2016Health

About Shouyao Holding

Shouyao Holdings (Beijing) Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of small molecule innovative drugs. Founded on April 19, 2016, by Chairman and General Manager Li Wenjun, the company has established a comprehensive R&D system that integrates AI drug design, medicinal chemistry, biology, and clinical research. Li, who holds a master's degree in business administration from Peking University, leads the company with the mission to develop affordable Class 1 innovative drugs for patients in China. The core of Shouyao's operations is its subsidiary, CellynTel, which has been engaged in small molecule drug R&D since 2010.

The company's business model encompasses both independent research and collaborative development. For its independent pipeline, Shouyao manages the entire process from drug discovery to commercialization. In its collaborative efforts, primarily with partners like Chia Tai Tianqing Pharmaceutical Group and Shijiazhuang Pharmaceutical Group, Shouyao is responsible for the preclinical discovery and screening of drug candidates. Following this initial stage, the partners handle subsequent clinical development, commercialization, and associated costs, while Shouyao retains co-ownership of intellectual property and rights to milestone payments and future sales royalties. This dual approach allows the company to advance a broad pipeline while managing R&D expenditures. The company went public on the Shanghai STAR Market on March 23, 2022, raising funds to advance its clinical trials and establish a new R&D and industrialization base.

Shouyao's product pipeline is robust and diversified, targeting key oncology indications such as non-small cell lung cancer (NSCLC), lymphoma, hepatocellular carcinoma, and pancreatic cancer, as well as other diseases like type II diabetes. The company's technology platform is centered on small molecule drugs, including proteolysis-targeting chimeras (PROTAC). A leading candidate, SY-707 (conteltinib), is a second-generation ALK inhibitor for ALK-positive NSCLC, which is currently in Phase III trials for first-line treatment and Phase II trials for second-line treatment. Other key pipeline assets include SY-3505, a third-generation ALK inhibitor, and inhibitors targeting KRAS, among others, with multiple products advancing through various stages of clinical trials.

Source: Dealroom company data

Shouyao Holding in the Dongcheng District ecosystem

Live from Dealroom

The Shouyao Holding office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • E-Town Capital
Employees 5 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shouyao Holding on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shouyao Holding on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.